HC Wainwright Estimates Alkermes’ Q3 Earnings (NASDAQ:ALKS)

Alkermes plc (NASDAQ:ALKS) – Equities research analysts at HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of Alkermes in a report issued on Wednesday, July 29th. HC Wainwright analyst D. Tsao now expects that the company will earn ($0.09) per share for the quarter, down from their previous estimate of $0.03. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Alkermes’ current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for Alkermes’ Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.43) EPS, FY2028 earnings at ($0.29) EPS, FY2029 earnings at $0.55 EPS and FY2030 earnings at $1.36 EPS.

A number of other analysts have also weighed in on ALKS. TD Cowen upped their target price on shares of Alkermes from $42.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, June 22nd. Zacks Research upgraded shares of Alkermes from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Wells Fargo & Company boosted their price target on shares of Alkermes from $44.00 to $65.00 and gave the company an “overweight” rating in a research report on Monday, June 29th. Royal Bank Of Canada upped their price target on shares of Alkermes from $45.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, June 9th. Finally, Mizuho increased their price objective on Alkermes from $53.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, July 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $54.56.

Alkermes Stock Performance

Shares of ALKS opened at $49.67 on Monday. The stock’s 50-day simple moving average is $48.74 and its 200 day simple moving average is $38.51. The stock has a market capitalization of $8.33 billion, a price-to-earnings ratio of 130.71 and a beta of 0.34. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.85 and a current ratio of 2.30. Alkermes has a 52-week low of $25.17 and a 52-week high of $55.67.

Insider Activity at Alkermes

In other news, EVP David Joseph Gaffin sold 2,034 shares of Alkermes stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $48.58, for a total transaction of $98,811.72. Following the completion of the sale, the executive vice president directly owned 225,456 shares of the company’s stock, valued at approximately $10,952,652.48. The trade was a 0.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher I. Wright sold 2,000 shares of the company’s stock in a transaction on Friday, June 12th. The stock was sold at an average price of $45.10, for a total transaction of $90,200.00. Following the completion of the transaction, the director owned 25,680 shares of the company’s stock, valued at $1,158,168. This trade represents a 7.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 79,574 shares of company stock worth $3,901,478 over the last quarter. 4.59% of the stock is currently owned by corporate insiders.

Institutional Trading of Alkermes

Several institutional investors have recently added to or reduced their stakes in the business. Norges Bank purchased a new position in shares of Alkermes in the fourth quarter worth about $54,442,000. Baker BROS. Advisors LP grew its position in Alkermes by 23.7% during the 4th quarter. Baker BROS. Advisors LP now owns 10,012,267 shares of the company’s stock worth $280,143,000 after acquiring an additional 1,920,916 shares during the last quarter. UBS Group AG grew its position in Alkermes by 237.4% during the 4th quarter. UBS Group AG now owns 2,544,895 shares of the company’s stock worth $71,206,000 after acquiring an additional 1,790,729 shares during the last quarter. First Trust Advisors LP increased its stake in Alkermes by 104.2% in the 1st quarter. First Trust Advisors LP now owns 2,968,785 shares of the company’s stock worth $104,976,000 after purchasing an additional 1,514,783 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in Alkermes by 32.0% in the 4th quarter. JPMorgan Chase & Co. now owns 5,184,547 shares of the company’s stock worth $145,064,000 after purchasing an additional 1,256,377 shares during the period. 95.21% of the stock is currently owned by hedge funds and other institutional investors.

Alkermes News Roundup

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Analysts maintain a generally favorable view of Alkermes, with the stock receiving a consensus rating of “Moderate Buy.” The broader analyst coverage includes several Buy or Overweight ratings, supporting investor confidence in the company’s outlook. Alkermes Receives Consensus Recommendation of Moderate Buy
• Neutral Sentiment: HC Wainwright issued an estimate for Alkermes’ third-quarter earnings, giving investors another reference point ahead of the results. The specific forecast was not provided, so the direct earnings implication remains unclear. HC Wainwright Estimates Alkermes’ Q3 Earnings
• Negative Sentiment: Director Nancy Lynn Md Snyderman sold 44,472 ALKS shares for approximately $2.24 million, reducing her direct ownership by about 74%. The unusually large reduction may weigh on sentiment, although insider selling does not necessarily indicate a deteriorating business outlook. SEC insider transaction filing
• Negative Sentiment: EVP Craig C. Hopkinson sold 9,000 shares valued at roughly $437,000, cutting his holdings by 11.48%. EVP David Joseph Gaffin also sold 2,034 shares for about $99,000, reducing his position by 0.89%. Both executive transactions were conducted under pre-arranged Rule 10b5-1 plans, which limits their value as discretionary bearish signals. Craig Hopkinson SEC insider transaction filing David Gaffin SEC insider transaction filing

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.